This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (155)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Urology  • Prostate Disease  • Oncology  • Prostate Cancer  • Alert me on articles by topic

Stephen J. Freedland, MD; Elizabeth B. Humphreys, BS; Leslie A. Mangold, MS; Mario Eisenberger, MD; Frederick J. Dorey, PhD; Patrick C. Walsh, MD; Alan W. Partin, MD, PhD

JAMA. 2005;294:433-439.

Context  The natural history of biochemical recurrence after radical prostatectomy can be long but variable. Better risk assessment models are needed to identify men who are at high risk for prostate cancer death early and who may benefit from aggressive salvage treatment and to identify men who are at low risk for prostate cancer death and can be safely observed.

Objectives  To define risk factors for prostate cancer death following radical prostatectomy and to develop tables to risk stratify for prostate cancer–specific survival.

Design, Setting, and Patients  Retrospective cohort study of 379 men who had undergone radical prostatectomy at an urban tertiary care hospital between 1982 and 2000 and who had a biochemical recurrence and after biochemical failure had at least 2 prostate-specific antigen (PSA) values at least 3 months apart in order to calculate PSA doubling time (PSADT). The mean (SD) follow-up after surgery was 10.3 (4.7) years and median follow-up was 10 years (range, 1-20 years).

Main Outcome Measure  Prostate cancer–specific mortality.

Results  Median survival had not been reached after 16 years of follow-up after biochemical recurrence. Prostate-specific doubling time (<3.0 vs 3.0-8.9 vs 9.0-14.9 vs 15.0 months), pathological Gleason score (7 vs 8-10), and time from surgery to biochemical recurrence (3 vs >3 years) were all significant risk factors for time to prostate-specific mortality. Using these 3 variables, tables were constructed to estimate the risk of prostate cancer–specific survival at year 15 after biochemical recurrence.

Conclusion  Clinical parameters (PSADT, pathological Gleason score, and time from surgery to biochemical recurrence) can help risk stratify patients for prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. These preliminary findings may serve as useful guides to patients and their physicians to identify patients at high risk for prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy to enroll them in early aggressive treatment trials. In addition, these preliminary findings highlight that survival in low-risk patients can be quite prolonged.

Author Affiliations: The James Buchanan Brady Urological Institute (Drs Freedland, Eisenberger, Walsh, and Partin and Mss Humphreys and Mangold) and the Departments of Urology (Drs Freedland, Eisenberger, Walsh, and Partin and Mss Humphreys and Mangold) and Oncology (Dr Eisenberger), The Johns Hopkins Medical Institutions, Baltimore, Md, and The Biostatistics Core, University of Southern California, Keck School of Medicine at Childrens Hospital Los Angeles, Los Angeles (Dr Dorey).

RELATED LETTERS

Mortality Following Prostate Cancer Recurrence After Radical Prostectomy
Thomas D. Trainer
JAMA. 2005;294(23):2969.
EXTRACT | FULL TEXT  

Mortality Following Prostate Cancer Recurrence After Radical Prostectomy—Reply
Stephen J. Freedland, Elizabeth B. Humphreys, Leslie A. Mangold, Alan W. Partin, Mario Eisenberger, and Frederick J. Dorey
JAMA. 2005;294(23):2969-2970.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy
Anthony V. D’Amico, Andrew A. Renshaw, Brenda Sussman, and Ming-Hui Chen
JAMA. 2005;294(4):440-447.
ABSTRACT | FULL TEXT  

PSA Kinetics and Risk of Death From Prostate Cancer: In Search of the Holy Grail of Surrogate End Points
Mitchell S. Anscher
JAMA. 2005;294(4):493-494.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy
Donovan et al.
JCO 2008;26:3923-3929.
ABSTRACT | FULL TEXT  

The postchemotherapy PSA surge syndrome
Thuret et al.
Ann Oncol 2008;19:1308-1311.
ABSTRACT | FULL TEXT  

Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers
Shariat et al.
Clin. Cancer Res. 2008;14:3785-3791.
ABSTRACT | FULL TEXT  

Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry
Veltri et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:102-110.
ABSTRACT | FULL TEXT  

Utilizing the Tumor-Node-Metastasis Staging for Prostate Cancer: The Sixth Edition, 2002
Chang and Amin
CA Cancer J Clin 2008;58:54-59.
ABSTRACT | FULL TEXT  

A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome
Yu et al.
Cancer Res. 2007;67:10657-10663.
ABSTRACT | FULL TEXT  

Prognostic Significance of p53 and X-ray Repair Cross-complementing Group 1 Polymorphisms on Prostate-Specific Antigen Recurrence in Prostate Cancer Post Radical Prostatectomy
Huang et al.
Clin. Cancer Res. 2007;13:6632-6638.
ABSTRACT | FULL TEXT  

A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis
Armstrong et al.
Clin. Cancer Res. 2007;13:6396-6403.
ABSTRACT | FULL TEXT  

Roles for the Stem Cell Associated Intermediate Filament Nestin in Prostate Cancer Migration and Metastasis
Kleeberger et al.
Cancer Res. 2007;67:9199-9206.
ABSTRACT | FULL TEXT  

Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy
Bastian et al.
Clin. Cancer Res. 2007;13:5361-5367.
ABSTRACT | FULL TEXT  

Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer
Shariat et al.
Clin. Cancer Res. 2007;13:5377-5384.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies
Lecouvet et al.
JCO 2007;25:3281-3287.
ABSTRACT | FULL TEXT  

Efficiency of Ultrasensitive Prostate-specific Antigen Assay in Diagnosing Biochemical Failure After Radical Prostatectomy
Shimizu et al.
Jpn J Clin Oncol 2007;37:446-451.
ABSTRACT | FULL TEXT  

Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson et al.
JCO 2007;25:2035-2041.
ABSTRACT | FULL TEXT  

Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality
Freedland et al.
JCO 2007;25:1765-1771.
ABSTRACT | FULL TEXT  

Docetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate Cancer
Taplin et al.
JCO 2006;24:5408-5413.
ABSTRACT | FULL TEXT  

Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall et al.
JNCI J Natl Cancer Inst 2006;98:1420-1424.
ABSTRACT | FULL TEXT  

Six-Month Androgen Suppression Plus Radiation Therapy Compared With Radiation Therapy Alone for Men With Prostate Cancer and a Rapidly Increasing Pretreatment Prostate-Specific Antigen Level
D'Amico et al.
JCO 2006;24:4190-4195.
ABSTRACT | FULL TEXT  

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition
Stephenson et al.
JCO 2006;24:3973-3978.
ABSTRACT | FULL TEXT  

Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment
Ferrari et al.
JCO 2006;24:3081-3088.
ABSTRACT | FULL TEXT  

Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer.
Pantuck et al.
Clin. Cancer Res. 2006;12:4018-4026.
ABSTRACT | FULL TEXT  

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
Stephenson et al.
JNCI J Natl Cancer Inst 2006;98:715-717.
ABSTRACT | FULL TEXT  

Mortality Following Prostate Cancer Recurrence After Radical Prostectomy
Trainer
JAMA 2005;294:2969-2969.
FULL TEXT  

Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy
Slovin et al.
Clin. Cancer Res. 2005;11:8669-8673.
ABSTRACT | FULL TEXT  

Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy
Lee and D'Amico
JCO 2005;23:8192-8197.
ABSTRACT | FULL TEXT  

Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy
Freedland et al.
Clin. Cancer Res. 2005;11:7735-7742.
ABSTRACT | FULL TEXT  

Radiation Dose Escalation as Treatment for Clinically Localized Prostate Cancer: Is More Really Better?
DeWeese and Song
JAMA 2005;294:1274-1276.
FULL TEXT  

PSA Kinetics and Risk of Death From Prostate Cancer: In Search of the Holy Grail of Surrogate End Points
Anscher
JAMA 2005;294:493-494.
FULL TEXT